Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Women with early, low-risk hormone receptor-positive breast cancer are significantly less likely to see their disease return if given radiation therapy and hormone therapy following surgery, according to a ... Read more
Breast cancer surgery with negative or clear margins, which leaves no signs of cancer behind, stimulates a protective anticancer immune response that reduces the risk of cancer spread to other ... Read more
AstraZeneca is starting a collaboration with Daiichi Sankyo for the global production and commercialization of trastuzumab deruxtecan (DS-8201), a novel antibody-drug conjugate under clinical studies for the treatment of advanced ... Read more
First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results ... Read more
Combining Tecentriq (atezolizumab) with the chemotherapy Abraxane (nab-paclitaxel) extends overall survival, and survival without cancer progression, in patients with triple negative breast cancer (TNBC) whose cancer is locally advanced ... Read more
Combining a new blood-based diagnostic test called Videssa Breast with breast imaging can improve breast cancer detection, reduce false diagnosis rates, and avoid unnecessary breast biopsies in women older ... Read more
Pin It on Pinterest